Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate Cancer

• Published in: The New England journal of medicine Vol. 341; no. 24; pp. 1781 - 1788
• Main Authors: Messing, Edward M, Manola, Judith, Sarosdy, Michael, Wilding, George, Crawford, E. David, Trump, Donald
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 09.12.1999
• Subjects: Aged; Antineoplastic agents; Antineoplastic Agents, Hormonal - therapeutic use; Biological and medical sciences; Cancer therapies; Combined Modality Therapy; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Disease Progression; Follow-Up Studies; Goserelin - therapeutic use; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Medical sciences; Men; Middle Aged; Neoplasm Recurrence, Local - prevention & control; Orchiectomy; Pharmacology. Drug treatments; Prostate cancer; Prostatectomy; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - mortality; Prostatic Neoplasms - pathology; Prostatic Neoplasms - surgery; Radiation therapy; Survival Analysis; Time Factors; Antineoplastic agent; Human; Urinary system disease; Prostate disease; Peptide hormone; Gonadotropin RH; Antiandrogen; Male; Malignant tumor; Survival; Time lag; Hypothalamic hormone; Treatment; Surgery; Evolution; Prostatectomy; Combined treatment; Male genital diseases; Goserelin; Prostate
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM199912093412401

Androgen-ablation therapy has been a mainstay of treatment for prostatic adenocarcinoma since the pioneering work of Huggins and coworkers nearly 60 years ago. 1 , 2 However, its role as a primary therapy for early stages of prostate cancer and the timing of its administration in advanced disease have been the subjects of considerable debate. Indeed, since the clinical trials of the Veterans Administration Co-operative Urological Research Group, which were conducted during the 1960s and early 1970s, the concept that early hormonal therapy retarded disease progression but did not prolong survival has been part of the dogma of prostate-cancer therapy. 3 , 4 In . . .